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Abstract: 28 
 29 
Blockade of inhibitory receptors (IR), overexpressed by T-cells, can activate anti-tumor 30 
immune responses resulting in the most promising therapeutic approaches, particularly in 31 
bladder cancer, currently able to extend patient survival.  Thanks to their ability to cross-32 
present antigens to T cells, dendritic cells (DC) are an immune cell population playing a 33 
central role in the generation of effective anti-tumor T-cell responses. While function and 34 
expression of IRs have been mostly investigated in T cells, very few data are available for 35 
DC. Therefore, we analyzed whether DC may express IRs able to decrease their functions. 36 
For that purpose, we investigated several IR: PD-1, CTLA-4, BTLA, TIM-3 and CD160, in 37 
circulating CD1c+ DC, CD141+ DC and plasmacytoid DC (pDC) from healthy donors (HD) 38 
and urothelial cancer (UCa) patients. Different DC subsets expressed BTLA and TIM-3 but 39 
not other IRs. More importantly BTLA and TIM-3 were significantly upregulated in DC from 40 
blood of UCa patients. Locally, bladder tumor-infiltrating DC also overexpressed BTLA and 41 
TIM-3 compared to DC from paired non-tumoral tissue. Finally, in vitro functional 42 
experiments showed that ligand-mediated engagement of BTLA and TIM-3 receptors 43 
significantly reduced the secretion of effector cytokines by DC subpopulations. Our findings 44 
demonstrate that UCa induces local and systemic overexpression of BTLA and TIM-3 by DC 45 
that may result in their functional inhibition, highlighting those receptors as potential targets 46 
for UCa treatment. 47 
 48 
Patient summary: In this report, we investigated patients with urothelial carcinoma with 49 
regard to expression and function of a panel of inhibitory receptors by dendritic cells (DC), an 50 
immune cell subpopulation which is critical in the initiation of protective immune responses. 51 
We found high expression of BTLA and TIM-3 by blood and tumor DC, potentially 52 
mediating decreased DC function, suggesting that BTLA and TIM-3 might be new interesting 53 
targets for urothelial carcinoma treatment. 54 
 55 
Take Home Message: The inhibitory receptors BTLA and TIM-3 are overexpressed on 56 
circulating and intratumoral dendritic cells in urothelial cancer patients, mediating reduction 57 
of dendritic cells function. 58 
 59 
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Main Text 61 
Immune responses are tightly regulated by activatory and inhibitory receptors (IR), also 62 
called immune checkpoints. Engagement of IR, upon interaction with their cognate ligands, 63 
leads to dimming the T-cell receptor signaling, resulting in reduction of immune responses to 64 
antigen [1]. The expression of IR has been associated to T-cell exhaustion in autoimmune 65 
diseases, chronic infections and cancers and to the impotence of T-cells to eradicate tumors 66 
[2]. Over the past few years, the therapeutic use of humanized antagonist antibodies against 67 
IR or their ligands has shown unprecedented clinical results in patients with solid tumors, 68 
particularly in muscle invasive bladder cancer (MIBC) patients [1, 3], demonstrating the great 69 
potential of such approaches and leading to a breakthrough therapy designation by the 70 
American Food and Drug Administration. Albeit IR have been extensively studied in T-cell 71 
subpopulations, almost no data are available on IR expression and function by dendritic cell 72 
(DC) subsets in humans. DC are key players in the initiation and regulation of immune 73 
responses. Indeed, DC are able to uptake, process, and present tumor antigens to other 74 
immune cells, so that they are crucial to “prime”/activate anti-tumor T-cell responses 75 
eventually leading to tumor-cell killing. Notably, DC are thus prominent targets in cancer 76 
immunotherapy strategies [4]. Human circulating DC can be broadly categorized into two 77 
groups: CD11cnegCD123+ plasmacytoid DC (pDC) and conventional CD11c+CD123neg DC 78 
(cDC) [5]. Among the cDC, two subpopulations have been identified according to the 79 
expression of CD1c (also known as BDCA-1) and CD141 (also known as BDCA-3 or 80 
thrombomodulin) [5]. CD141+ DC have prominent capacities to cross-present antigen after its 81 
uptake and thus may play a major role for inducing anti-tumor immune responses [5, 6]. Here, 82 
we have conducted the first analysis of the expression and function of several well-known IR 83 
on DC subsets from healthy donors (HD) and urothelial cancer (UCa) patients. 84 
Expression of Programmed cell Death-1 (PD-1; CD279), Cytotoxic T Lymphocyte 85 
Associated protein-4 (CTLA-4; CD152), B an T Lymphocyte Attenuator (BTLA; CD272), 86 
CD160 (BY55) and T-cell Immunoglobulin and Mucin-domain containing-3 (TIM-3; CD366) 87 
was first assessed by flow cytometry on circulating DC subpopulations from HD and UCa 88 
patients. pDC and conventional CD1c+ and CD141+ DC were identified using a combination 89 
of phenotypic markers (Supplementary Fig. 1) and expression of IR was determined. PD-1, 90 
CTLA-4 and CD160 were not expressed by any subtype of DC from HD or UCa patients 91 
(data not shown). In contrast, BTLA was observed in all DC subsets, albeit at a very low level 92 
in CD1c+ DC and TIM-3 was only expressed by CD1c+ and CD141+ DC, in HD. Comparison 93 
to UCa patients showed that BTLA was significantly overexpressed by CD141+ DC and pDC, 94 
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whereas only a slight increase of TIM-3 expression was observed in CD141+ DC (Fig. 1A). 95 
This result suggests that bladder tumor microenvironment may increase BTLA and TIM-3 96 
expression on DC. In order to have more insights into BTLA and TIM-3 expression by DC, 97 
we segregated the data from UCa patients in two groups, according to the stage of the disease 98 
(Supplementary Table 1): non-muscle invasive bladder cancer (NMIBC) and MIBC patients. 99 
A significantly higher expression of TIM-3 was only found in CD141+ DC from MIBC 100 
patients as compared to HD, suggesting that UCa-mediated overexpression of TIM-3 is later 101 
than for BTLA, which was overexpressed in CD141+ DC and pDC from both types of patients 102 
(Supplementary Fig. 2). 103 
Seeking further evidence that BTLA and TIM-3 expression may be altered by the bladder 104 
tumor microenvironment, we analyzed their expression on tissue-infiltrating DC 105 
subpopulations from bladder tumor and paired non-tumoral adjacent tissue from surgical 106 
specimen recovered after cystectomy. Since DC subtypes from tissue are phenotypically 107 
different than circulating DC, we focused on CD14+CD11c+ and CD14negCD11c+ tissue-108 
infiltrating DC [7, 8] (Fig. 1B). Notably, we observed a significant overexpression of TIM-3 109 
in both types of bladder DC and a higher frequency of BTLA+ CD14negCD11c+ bladder DC 110 
within tumor tissue (Fig. 1C). Similar results were obtained when comparing non-paired 111 
tissue samples (Supplementary Fig. 3). 112 
We next sought to determine whether BTLA and TIM-3 expressed on DC are functional 113 
and could lead to an inhibition of DC function, as monitored by cytokine (IL-12, IL-1β and 114 
TNF-α) production, upon recombinant HVEM (BTLA ligand) or galectin-9 (TIM-3 ligand) 115 
binding. Thus, sorted CD1c+ and CD141+ DC were stimulated by polyionosinic-polycytidylic 116 
acid (Poly(I:C)) and pDC by CpG oligodeoxynucleotides (CpG ODN). In the presence of 117 
either HVEM or galectin-9, we observed a decrease of the cytokine secretion by CD141+ DC 118 
(Fig. 2A). In addition, CD1c+ DC produced less IL-12p70 and IL-1β upon galectin-9 ligation 119 
(Fig. 2B). In pDC, only IL-12p70 production was affected by the presence of HVEM (Fig. 120 
2C). These data suggest a functional inhibition of DC subpopulations via BTLA/HVEM or 121 
TIM-3/galectin-9 interactions. 122 
In this study, we present the first analysis of several IR on DC subsets from HD and UCa 123 
patients. We found that BTLA and TIM-3 are differentially expressed across circulating and 124 
tissue DC subsets. Moreover, our results indicate that UCa promotes the overexpression of 125 
BTLA and TIM-3 on DC, similarly to what has been described for T-cells [9, 10]. In contrast 126 
to the relatively well-known mechanisms of T-cell function dampening upon TIM-3/galectin-127 
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9 binding, TIM-3 function in myeloid cells, particularly in DC, remains controversial. Indeed, 128 
while recent reports, in accordance with our results, show that TIM-3 may reduce DC 129 
functions, other reports also described a positive co-stimulatory effect of TIM-3 on DC upon 130 
galectin-9 ligation [11]. 131 
In our settings, we did not observe any PD-1 expression by circulating DC from either HD 132 
or UCa patients. It has been recently reported that mouse DC expressing PD-1 showed 133 
reduced function in ovarian and hepatocellular tumor models [12, 13]. Authors also observed 134 
PD-1+ tumor-infiltrating DC in human ovarian tumors. Thus, further investigation is 135 
warranted to determine PD-1 expression in bladder tumor DC. 136 
Immune regulatory mechanisms are emerging as important targets to attenuate 137 
autoimmune diseases or enhance immune responses to tumors and infections. Therapies 138 
aimed at overcoming mechanisms of peripheral immune tolerance, in particular by blocking 139 
inhibitory checkpoints, offer the potential to generate anti-tumor activity, either as 140 
monotherapies or in synergy with other therapies [1] that directly or indirectly enhance 141 
presentation of tumor antigens to the immune system. Checkpoint blockade therapy targeting 142 
IR expressed by T-cells and DC simultaneously, such as BTLA and TIM-3, may therefore 143 
prove critical in the generation of a potent antitumor immune response, particularly in 144 
urothelial cancer. 145 
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Figure legends: 210 
 211 
Figure 1: Overexpression of BTLA and TIM-3 in circulating and tumor-infiltrating DC 212 
subsets. (A) Comparison of BTLA and TIM-3 expression in CD1c+, CD141+ and pDC from 213 
peripheral blood mononuclear cells (PBMC) of HD (n=15) and UCa patients (n=40). (B) 214 
Representative example of BTLA and TIM-3 labeling in CD14+CD11c+ and CD14negCD11c+ 215 
DC infiltrating the bladder from MIBC patients. (C) Quantification of BTLA and TIM-3 216 
expressed by bladder infiltrating DC. *p<0.05; **p<0.01. RFI: Ratio of mean-Fluorescence-217 
Intensity of specific staining versus isotype Ig control, except for BTLA in CD14negCD11c+ 218 
DC expressed in percentage of positive cells, since bimodal population was observed. 219 
 220 
Figure 2: Functional inhibition of DC subsets by BTLA and TIM-3. Sorted circulating 221 
CD141+ (A) and CD1c+ (B) DC from HD were stimulated overnight by Poly(I:C) in the 222 
presence of plate bound Galectin-9, whereas sorted pDC (C) were activated by CPG in the 223 
presence of coated HVEM. After overnight incubation, IL-12p70, IL-1β and TNF-α secretion 224 
was determined in supernatant. *p<0.05. 225 
 226 
 227 
Supplementary Figure legends: 228 
 229 
Supplementary Figure 1: Identification of DC subsets by flow cytometry. Representative 230 
example of direct ex vivo HLA-DR, CD1c, CD141, CD123 staining after lineage (i.e. CD3, 231 
CD14, CD16, CD19, CD20, CD56), doublets and dead cell exclusion from PBMC of HD. 232 
pDC were identified as LinnegHLA-DR+CD123+, CD1c+ DC as LinnegHLA-DR+CD1c+ and 233 
CD141+ DC as LinnegHLA-DR+CD141+. 234 
 235 
Supplementary Figure 2: BTLA and TIM-3 expression in DC subpopulations from 236 
PBMC of HD, NMIBC and MIBC patients. Quantification of BTLA and TIM-3 expressed 237 
by CD1c+, CD141+ DC and pDC in PBMC of UCa patients according to invasiveness of the 238 
tumor. *p<0.05; **p<0.01. 239 
 240 
Supplementary Figure 3: Overexpression of BTLA and TIM-3 in bladder-infiltrating 241 
DC subsets. Quantification of BTLA and TIM-3 expressed by CD14+CD11c+ and 242 
CD14negCD11c+ DC from bladder tumor or non-tumor adjacent tissue from different patients. 243 
*p<0.05. 244 
 245 
Supplementary materials and methods 
 
Patient selection 
Buffy coats from healthy subjects were purchased from the Blood Transfusion Center, 
Epalinges, Switzerland. Peripheral blood and bladder tissue from patient were obtained after 
written consent and full ethics approval (protocol #119/10). Bladder tissue samples were 
carefully collected by pathologist from tumor and non-tumoral adjacent tissue at a resection 
margin located at a mean distance of 2 cm from the tumor. Bladder cells were then 
fractionated as described previously [1] and were subsequently used for flow cytometry 
analysis. The pathological characteristics of patients are summarized in Supplementary Table 
1. 
 
Flow cytometry and cell sorting 
The following antibodies to human proteins were used. From Biolegend: anti-CD1c-PerCP-
Cy5.5, anti-CD123-PE-Cy7, anti-TIM-3-BV421, anti-CTLA-4-PE, anti-PD-1-BV421 and 
mouse IgG1-BV421. From Becton Dickinson: Lineage1 cocktail-FITC (anti-CD3, anti-CD14, 
anti-CD16, anti-CD19, anti-CD20 and anti-CD56) and anti-BTLA-PE. From Beckman 
Coulter: anti-CD160-PE. From Thermo Fisher Scientific: anti-HLA-DR-PE/TexasRed. From 
Miltenyi Biotec: anti-CD141-APC. From eBioscience: mouse IgG1-PE. 
PBMCs were obtained by density centrifugation using Lymphoprep (Axis-Shieldy) and 
cryopreserved in RPMI1640 supplemented with 40% FCS and 10% DMSO. Surface labelling 
was performed for 20 min. at 4 C, as described previously [1]. Cells were then stained for 
dead cell exclusion with aqua live/dead stain kit (Life Technologies) according to the 
manufacturer’s instructions. FcR Blocking Reagent (Miltenyi Biotec) was used during cells 
labelling to block unwanted binding of antibodies. Sample acquisition was performed on 
Gallios Flow-Cytometer (Beckman Coulter) and data were analyzed using the FlowJo 
Software (TreeStar). 
For cell sorting (Astrios, Beckman Coulter), DC were magnetically enriched from 3-4x108 
PBMC from healthy individuals using the Dynabeads® human DC enrichment kit (Thermo 
Fisher Scientific). Cells were subsequently stained and live Linneg HLA-DR+ cells were sorted 
into the indicated subsets using Astrios cell sorter (Beckman Coulter). 
 
Inhibition assay 
Sorted DC subpopulations were activated by 1 μg/ml of poly (I:C) or ODN CpG (Pfizer/ 
Coley Pharmaceutical Group) and cultured with 10 μg/ml plate-bound recombinant human 
HVEM-Fc chimera (R&D Systems), soluble recombinant human Galectin-9 (Biolegend) or 
with Control-Fc (Ctrl) fusion protein (Mutated Thy-1-Fc, Enzo Life Sciences). After 
overnight incubation, culture supernatants were tested for the presence of IL-12p70, IL-1β 
and TNF-α by Cytokines Beads Array (BD Biosciences). 
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism 6 and included unpaired 
(Supplemental Fig.2) or paired (Fig. 1C and 2) two-tailed Student’s t-test or one-way 
ANOVA followed by Dunnett’s test (Fig. 1A) for comparing the means of two or multiple 
groups, respectively. p values below 0.05 were considered statistically significant. 
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Supplementary Table 1. Characteristics of patients  
Patient All patients 
Number of patients 40 
Age, yr, median (IQR) 71 (62.25 – 75) 
Sex, n (%)  
Male 32 (80) 
Female 8 (20) 
Tumor status, n (%)  
NMIBC  
pTa 14 (35) 
pT1 6 (15) 
MIBC  
pT2 7 (17.5) 
pT3 11 (27.5) 
pT4 2 (5) 
Draining lymph nodes status  
N0 10 (50) 
N1 5 (25) 
>N2 1 (5) 
NA 4 (20) 
Adjuvant chemotherapy 5 (25) 
NMIBC = Non Muscle Invasive Bladder Cancer 
MIBC = Muscle Invasive Bladder Cancer 
NA = Not Available 
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